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Tyrosin kinase inhibitors (TKI) sharply improved the prognosis of Chronic Myeloid
Leukemia (CML) and of Philadelphia+ Acute Lymphoblastic Leukemia (Ph+ALL) patients.
However, TKI are not curative because of the development of resistance and
lack of complete molecular remission in the majority of patients. Clinical evidences
would support the notion that patient’s immune system may play a key role in
preventing relapses. In particular, increased proportions of terminally differentiated
CD56+CD16+CD57+ NK cells have been reported to be associated with successful
Imatinib therapy discontinuation or with a deep molecular response in Dasatinib-treated
patients. In view of the potential role of NK cells in immune-response against
CML, it is important to study whether any TKI have an effect on the NK cell
development and identify possible molecular mechanism(s) by which continuous
exposure to in vitro TKI may influence NK cell development and repertoire. To
this end, CD34+ hematopoietic stem cells (HSC) were cultured in the absence or
in the presence of Imatinib, Nilotinib, or Dasatinib. We show that all compounds
exert an inhibitory effect on CD56+ cell recovery. In addition, Dasatinib sharply
skewed the repertoire of CD56+ cell population, leading to an impaired recovery
of CD56+CD117−CD16+CD94/NKG2A+EOMES+ mature cytotoxic NK cells, while
the recovery of CD56+CD117+CD94/NKG2A−RORγt+ IL-22-producing ILC3 was not
affected. This effect appears to involve the Dasatinib–mediated inhibition of Src kinases
and, indirectly, of STAT5-signaling activation in CD34+ cells during first days of culture.
Our studies, reveal a possible mechanism by which Dasatinib may interfere with the
proliferation and maturation of fully competent NK cells, i.e., by targeting signaling
pathways required for differentiation and survival of NK cells but not of ILC3.
Keywords: innate lymphocyte cells, NK cell development, tyrosin kinase inhibitors, CML-chronic myelogenous
leukemia, ILC3
INTRODUCTION
Therapy with tyrosin kinase inhibitors (TKI) has greatly improved the prognosis of Chronic
Myeloid Leukemia (CML) and of Philadelphia+ Acute Lymphoblastic Leukemia (Ph+ALL)
patients (1–3). However, despite their efficacy, TKI cannot be considered as curative therapeutic
agents, because the majority of patients develop resistance or lack complete molecular remission
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(4–6). Moreover, patients undergoing life-long treatment may
experience adverse effects that compromise their quality of life
(6–8). Thus, during the past several years, the achievement of
therapy discontinuation, allowing long treatment-free remissions
(TFR) became a main area of investigation (8). Recent clinical
trials indicated that ∼40% of patients with deep molecular
response (DMR), who undergo therapy discontinuation, remain
free of relapse for several years (8–10). Clinical evidences would
support the notion that the patient’s immune system may play a
key role either by eradicating leukemia or by exerting a successful
long-lasting control of residual leukemic cells. Indeed, patients
with an efficient effector arm of their immune system display
a significantly longer TFR with a DMR (11–13). Thus, ongoing
major efforts are aimed to identify immune mechanisms and
biomarkers that may help to select patients who are suitable for
successful therapy discontinuation upon achievement of a DMR.
In this context, analysis of natural killer (NK) cells, capable of a
potent anti-leukemia activity, could offer a clue to identify such
patients (14).
NK cells represent an important component of the innate
immunity. Their function is finely tuned by inhibitory and
activating receptors. Remarkably, NK cells have been shown
to play an important role in the favorable clinical outcome
of patients with high risk leukemias undergoing haploidentical
Hematopoietic Stem Cell Transplant (15–18). NK cells can
recognize and kill leukemic blasts, particularly those displaying
down-regulation of HLA-class I molecules (failing to interact
with HLA-specific inhibitory NK receptors such as KIR and
CD94/NKG2A), and/or over-expressing ligands recognized by
activating NK receptors (including Natural Cytotoxic Receptors,
NCR, NKG2D and DNAM-1) (16, 19). Certain activating KIR,
present only in some individuals, may also positively contribute
to the anti-leukemia activity (14, 20, 21).
NK cell development occurs primarily in the bone marrow
(BM), requires the expression of E4BP4 (NFIL3), Tbx21
(T-bet), eomesodermin (EOMES) transcription factors (TF),
and proceeds through a multi-step process, characterized
by the sequential acquisition of surface receptor markers
(including CD161, CD56, CD94/NKG2A, LFA-1, CD16, KIRs,
and CD57) and given functional capabilities (22–24). NK
cells are developmentally related to Innate Lymphoid Cells
(ILCs) as they derive from a common DNA-binding protein
inhibitor (ID2)-positive hematopoietic precursor (24). Members
of ILC family are thought to play a relevant role in innate
defenses against pathogens, in epithelial tissue homeostasis
and in lymphoid structure organization. Three main groups
of ILCs have been identified: ILC1, ILC2, and ILC3, on
the basis of their cytokine profile and transcription factors
(TF) required for their differentiation (25). In vitro models
of human NK cell development from umbilical cord blood
(UCB)-derived CD34+ cells revealed that these precursors
can give rise both to NK cells and ILC3. The expression of
CD94/NKG2A and LFA-1 marks CD161+CD56+CD117−CD7+
NK cells that express NCR, cytolytic granules and production
of IFN-γ. On the other hand, the lack of expression of
CD94/NKG2A and LFA-1 (CD161+CD56+CD117+CD7−LFA-
1−CD94/NKG2A−) identifies a heterogeneous cell subset,
that may contain both NK cell precursors and ILC3,
characterized by the expression of RAR-related orphan
receptor gamma (RORγt) TF and by the ability to produce
IL-22 (26, 27).
In the past few years, the effects of TKI on the NK cell
repertoire and function have been analyzed in several studies
(28). Of note, increased proportions of terminally differentiated
cytolytic CD56+CD16+CD57+ NK cells were found in patients
that achieved a successful Imatinib therapy discontinuation or in
Dasatinib-treated patients with a DMR (12, 29–32). Recently, it
has also been suggested that KIR genotype may represent a new
biomarker for response to TKI therapy (33–35). On the other
hand, previous in vitro studies reported conflicting results on the
effect of different TKI on NK cell proliferation and function (28).
In view of the potential role of NK cells in the control of
CML, it is important to study the effect of TKI not only on
mature NK cells, but also on NK cells undergoing maturation.
Notably, TKI may impair hematopoiesis, consequent to the
inhibitory effect on c-KIT transduction pathway. Moreover,
Dasatinib inhibits Src kinase, also involved in the regulation of
hematopoiesis. Thus, it is possible that prolonged administration
of TKI may affect NK cell differentiation from Hematopoietic
Stem Cells (HSC) (24, 36–38). To explore this possibility,
whether indeed TKI could influence NK cell development
and repertoire, UCB-derived CD34+ HSC were cultured in
the absence or in the presence of Imatinib, Nilotinib, or
Dasatinib. Our results show that all compounds exert an
inhibitory effect on cell proliferation. In addition, Dasatinib
sharply skewed the repertoire of CD56+ cells, with an impaired
recovery of CD56+CD117−CD16+CD94/NKG2A+EOMES+
mature cytotoxic NK cells, paralleled by an enrichment
of CD56+CD117+CD94/NKG2A−RORγt+ ILC3. This effect
appears to involve the Dasatinib–mediated inhibition of Src
kinases. Our studies, revealed a mechanism by which Dasatinib
may interfere with the maturation of fully competent NK cells,
i.e., by targeting signaling pathways required for differentiation
of NK cells but not of ILC3.
MATERIALS AND METHODS
Cell Isolation and in vitro Culture
Liguria Cord Blood Bank provided UCB samples from healthy
individuals. Ethical Committee approved the study and
mothers gave their written informed consent according to
the Helsinki Declaration. Mononuclear cells were obtained
by Ficoll-Lympholyte (Cedarlane, Canada) separation.
CD56−CD34+ cells (>98% purity) were obtained by MACS
positive separation (Miltenyi Biotec, Germany). Cells were
cultured in RPMI 1640 (Lonza, Belgium) containing 10%
human AB serum (Biowest, France), Stem Cell Factor (SCF)
(10 ng/ml), Fms-related tyrosine kinase 3 ligand (FLT3-L)
(10 ng/ml), Interleukin-7 (IL-7) (20 ng/ml), Interleukin-15
(IL-15) (20 ng/ml), Interleukin-21 (IL-21) (20 ng/ml) (Miltenyi
Biotec,), in the absence or in the presence of: Imatinib (IM
5µM), Nilotinib (NIL 3, 6µM), Dasatinib (DAS 200 nM)
(Selleck Chemicals, USA) at the plasma concentration 30min
post administration, or with Dimethyl sulfoxide (DMSO) at the
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corresponding concentration of the drugs (D 1:1,000/1:25,000)
(Sigma-Aldrich, USA) or with KX2-391 used at different
concentrations (Selleck Chemicals). We added TKI, DMSO,
or KX2-391 at day 0 and at later intervals i.e., 24 h, 4, 10, or
15 days.
Monoclonal Antibodies (mAbs) and Flow
Cytometry
mAbs were purchased from several companies. A full list of the
mAbs utilized is provided in Table 1. All the mAbs were mouse-
anti human, with the exception of ROR-γt mAb, Phospho-Stat3
(Tyr705)(D3A7)XP mAb, and Phospho-Stat5 (Tyr694)(D47E7)
XP mAb were from Rabbit. To perform cell gating strategy we
first identifiedmorphological parameters using FSC-A vs. SSC-A.
Then, we performed a further gate in which we analyze the FSC-A
vs. FSC-H, in order to limit any interference due to doublets. To
assess cell viability we performed analyses with Propidium Iodide
and Annexin V.
Cell Cytotoxicity Assay
Cell cytotoxicity was analyzed in a 4 h 51Cr-release assay against
human leukemic K562 cell line. Cells were counted, washed
and plated. Effector/Target (E/T) cell ratio is 2/1. The effector
target ratio was normalized to the numbers of CD56+ cells
present in each culturing conditions. To this end, we adjusted
the number of effector cells in each condition accordingly to
the CD56+ cells present in the cultures and to the cell count
performed simultaneously by using MACSQuant flowcytometer.
Experiments were performed in duplicates. Data are expressed as
percentage of target cell lysis.
Intra-cytoplasmic Cytokine, Cytolytic
Granules, and TF Expression Assays
To detect cytokines, cells cultured in different conditions,
were washed, suspended and over night stimulated with IL-
12 (10 ng/ml), IL-15 (50 ng/ml), IL-18 (100 ng/ml), or IL-
1β (50 ng/ml), IL-7 (50 ng/ml), IL-23 (50 ng/ml) (Peprotech,
UK) in the presence of monensin (GolgiStop) or brefeldin
(GolgiPlug) (Biosciences), respectively. For intra-cytoplasmic
cytokine and cytolytic granules analyses, cells were stained
for surface markers and then fixed and permeabilized with
Fixation and Permeabilization Kit (BD Biosciences, New Jersey
USA). Then, cells were incubated with cytokine- or Perforin-
specific mAb. To detect TF expression, cells were suspended
in 5% BSA buffer, stained for surface markers, subsequently
fixed with Transcription Factor Staining Buffer Set (eBioscience-
ThermoFisher) and stained for RORγt, and EOMES TF; instead,
to detect expression of pSTAT3 and pSTAT5, cells were fixed with
PFA 4% andmethanol 100% and after that cells were stained with
anti-pSTAT antibodies.
Statistical Analysis
Prism GraphPad software was used for statistical analysis. We
considered significant P ≤ 0.05.
TABLE 1 | List of the mAbs used in the experiments.
Antigen Antibody
clone
Fluorochrome Supplier
CD56 N901 PeCy7 Beckman-Coulter
CD159a Z199 APC Beckman-Coulter
CD159a Z199 PE Beckman-Coulter
CD158a EB6B APC Beckman-Coulter
CD158b1,b2 GL183 APC Beckman-Coulter
CD158e1,e2 Z27.3.7 APC Beckman-Coulter
CD158a EB6B PE Beckman-Coulter
CD158b1,b2 GL183 PE Beckman-Coulter
CD158e1,e2 Z27.3.7 PE Beckman-Coulter
CD336 (NKp44) Z231 PE Beckman-Coulter
CD337 (NKp30) Z25 PE Beckman-Coulter
CD335 (NKp46) BAB281 PE Beckman-Coulter
CD33 AC104.3E3 APC Miltenyi Biotec
CD14 TÜK4 FITC Miltenyi Biotec
HLA-DR AC122 PerCP Miltenyi Biotec
CD16 REA423 FITC Miltenyi Biotec
CD11a (LFA-1) TS2/4 PerCP BioLegend
CD11a (LFA-1) TS2/4 FITC BioLegend
CD7 CD7-6B7 FITC BioLegend
CD335 (NKp46) 9E2 eFluor450 BioLegend
CD117 (c-KIT) 104D2 PerCP-Cy5.5 BioLegend
CD161 HP-3G10 PerCP-Cy5.5 BioLegend
CD226 (DNAM-1) 11A8 PE BioLegend
CD94 DX22 FITC BioLegend
CD336 (NKp44) P44-8 AF-647 BioLegend
CD337 (NKp30) P30-15 AF-647 BioLegend
CD16 3G8 BV-421 BioLegend
CD127 A019D5 BV-421 BioLegend
CD132 TUGh4 APC Biolegend
CD14 61D3 eFluor450 eBioscience-
ThermoFisher
CD117 104D2 BV-421 eBioscience-
ThermoFisher
CD14 61D3 APC-eFluor-780 eBioscience-
ThermoFisher
IL-22 22URTI PE eBioscience-
ThermoFisher
ROR-γt AFKJS-9 PE eBioscience-
ThermoFisher
EOMES WD1928 eFluor-660 eBioscience-
ThermoFisher
Perforin dG9 PE eBioscience-
ThermoFisher
IFN-γ 4S.B3 eFluor450 eBioscience-
ThermoFisher
TNF-α MAb11 eFluor450 eBioscience-
ThermoFisher
CXCL8 6217 PE R & D system
pSTAT3 XP rabbit
(Tyr705)
D3A7 Unconjugated Cell signaling
pSTAT5 XP rabbit
(Tyr694)
D47E7 Unconjugated Cell signaling
Goat-anti rabbit
(IgG H + L) IgG1
A27034 AF-488 Invitrogen-
ThermoFisher
CD122 Mik-β2 PE BD Pharmingen
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RESULTS
TKI Inhibit in vitro Proliferation of Myeloid
and Lymphoid Precursors From CD34+
HSC
In order to analyze the effects of different TKI on in vitro
NK cell differentiation, UCB-CD34+ HSC were isolated and
cultured with cytokines (SCF, FLT3-l, IL-7, IL-15 and IL-21,
see section Material and Methods), suitable to promote NK
cell differentiation, either in the absence (control = CTR) or
in the presence of different TKI at plasmatic concentrations:
Imatinib 5µM (IM), Nilotinib 3.6µM (NIL), Dasatinib 0.2µM
(DAS). DMSO was used as vehicle control. After 15 days of
culture, cells were counted and analyzed for informative surface
markers. As shown in Figure 1A, TKI led to a decreased
mono-nucleated cell recovery that was particularly sharp in
the case of Dasatinib. Evaluation of the surface staining for
Annexin V after 3 and 8 days of culture suggested that the
strong reduction of cell numbers detected in the presence of
Dasatinib may be due to an increased programmed cell death,
occurring during the first week of culture (Figure 1B). The
analysis of informative cell surface markers indicated that the
recovery of both CD33+CD14−myeloid cells and CD33+CD14+
monocytes, was sharply reduced in the presence of all TKI
analyzed (Figure 1C). Remarkably, all TKI induced a significant
reduction of CD161+CD56+ absolute cell numbers as compared
to controls. Also in this case, the effect was most striking in
the presence of Dasatinib (Figure 1D). Of note, results obtained
in cultures performed in the presence of Dasatinib displayed a
sharp significant difference also with cultures performed in the
presence of DMSO 1:25,000 (Figures 1A,C,D). Since cultures
performed with DMSO at the final concentrations of 1:25,000 did
not substantially differ in cell recovery from the CTR cultures,
data on the cultures performed with DMSO at this concentration
will not be shown any further.
Dasatinib Skews in vitro Cell Differentiation
of CD161+CD56+ Precursors Toward ILC3
Next, we analyzed the surface phenotype of CD161+CD56+
cells obtained after 25 days under the culture conditions
indicated above. As shown in Figure 2A, analysis of the receptor
repertoire of CD56+ cells revealed a significant reduction
of CD56+CD94/NKG2A+ cells in the presence of Dasatinib,
while the percentages of CD56+CD117+ cells were significantly
increased. Accordingly, also the percentages of NKG2D+,
DNAM-1+, and CD16+ cells were reduced as compared
to controls (Figure 2B). Figure 2C shows a representative
experiment: in the presence of Dasatinib, a major decrease of
percentages of CD56+ cells could be detected. Moreover, the
majority of CD56+ cells were represented by CD117+LFA-
1−CD94/NKG2A−CD16− cells, a subset that may include
both ILC3 and Stage III NK cell precursors (27). Thus, we
further analyzed the expression of RORγt and Eomes TF,
which allows discriminating ILC3 and stage IV/V NK cells.
This analysis revealed a significant increase of CD56+ RORγt+
ILC3 and a significant decrease of CD56+ Eomes+ NK cells as
compared to controls (Figures 3A,B), Of note, we could detect
higher percentages of CD56+CD117+CD127+(CD132+) cells in
cultures performed in the presence of Dasatinib as compared
to controls, while CD122+ cells were virtually undetectable
(Figure 3C).
CD161+CD56+ Cells Developed in the
Presence of Dasatinib Express Higher
Percentages of IFN-γ+ Cells but Display a
Reduced Cytolytic Activity
The altered composition of CD56+ cell subsets occurring in
the presence of Dasatinib, suggests that this compound may
affect NK cell differentiation and proliferation. To verify whether
TKI could also affect the functional activity of CD56+ cells,
we analyzed the intra-cytoplasmic cytokine expression and
the cytolytic activity against the NK-susceptible K562 human
leukemia cell line.
CD56+ lymphoid cells, developed in the absence or in
the presence of different TKI, were stimulated either with
IL-1β, IL-7, and IL-23, or with IL-12, IL-15, and IL-18 and
analyzed for intra-cytoplasmic cytokine expression by flow
cytometry. Figures 4A,B shows that CD56+CD117+CD94−
ILC3 subset, generated in the presence of Dasatinib, display
higher percentages of IL-22+ and IL-8+ cells and a slight increase
of IFN-γ+ cells. Interestingly, in the presence of Dasatinib, also
the small CD56+CD117−/+CD94+ cell subset, expressed higher
proportions of IFN-γ+ cells as compared to the other culturing
conditions (Figures 4A,B). Analysis of the cytolytic activity
against K562 target cells, indicated that CD56+ cells generated
in the presence of Nilotinib or Dasatinib, were significantly
less cytolytic (Figure 4C). Of note, the decreased cytotoxicity,
observed in the presence of Dasatinib, was associated to lower
percentages of CD56+ Perforin+ cells as compared to controls
(Figure 4D).
Inhibition of Src Kinases Skews CD56+
Cell Repertoire Undergoing in vitro Cell
Differentiation
It has been reported that Dasatinib, but not Imatinib and
Nilotinib, exerts an inhibitory effect on the family of Src kinases:
thus, it is possible that the lower numbers of CD56+ cells,
detected in the presence of this compound, may reflect an
inhibitory effect on Src kinases occurring at the level of cell
precursors (36, 39). To test this possibility, CD34+HSC were
cultured in appropriate cytokine mix medium in the absence
or in the presence of different concentrations of KX2-391 (5,
50, 100, and 200 nM) a non-selective Src kinase inhibitor, or in
the presence of Dasatinib (200 nM). After 15 days of culture,
cells were counted. KX2-391 did not significantly impair cell
proliferation at different drug concentrations with the exception
of highest dose (200 nM), in which an extensive cell death could
be detected (Figures 5A,B). Moreover, there were no significant
variations in CD56+ cell percentages in the presence of lower
concentrations of KX2-391 inhibitor as compared to controls
(Figure 5C). However, analysis of the cell surface phenotype
revealed that KX2-391 could induce substantial modifications of
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FIGURE 1 | TKI inhibit the in vitro cell differentiation of CD34+HSC toward myeloid and lymphoid cells. UCB-CD34+ cells were purified and cultured with
cytokine-mix medium in the absence (CTR, control) or in the presence of different TKI: Imatinib 5µM (IM) Nilotinib 3,6µM (NIL), Dasatinib 0,2µM (DAS) at the plasma
peak concentrations and DMSO at the corresponding concentrations of the drugs (D 1:1000 and D 1:25000). After 15 days of culture, cells were counted and
analyzed by flow-cytometry for the indicated surface markers. (A) The histogram shows the absolute mononucleated cell number recovery in CTR or TKI cultures. The
data are represented as the median with interquartile range obtained by ten independent experiments and analyzed by Kruskal-Wallis multiple comparison test (*p <
0.05;**p < 0.005;***p < 0.0005). (B) Dot plots show the morphological features and Annexin V/PI staining observed in the cell precursors undergoing in vitro NK cell
differentiation in the presence of different culturing conditions: control (CTR), Imatinib 5µM (IM), Nilotinib 3,6µM (NIL), Dasatinib 0,2µM (DAS) and DMSO (D 1:1000
and D 1:25000). The cells were undergone to immunofluorescence tests after 3 and 8 days of culture. (C) The histogram represents the fold change of absolute cell
numbers of CD33+CD14− and CD33+CD14+ cells recovered in TKI and DMSO cultures as compared to CTR, arbitrarily normalized to one. The data are expressed
as the median values with interquartile range obtained by ten independent experiments. Data obtained in different culturing conditions were compared to CTR and
analyzed by Wilcoxon signed-rank test (*p < 0.05;**p < 0.005;***p < 0. 0005;****p < 0.00005). Comparison between the different TKI culturing conditions and the
different DMSO diluition culturing conditions was analyzed by Kruskal–Wallis multiple comparison test (*p < 0.05; **p < 0.005). (D) The histogram represents the fold
change of CD161+CD56+ absolute cell number recovered in the presence of TKI and DMSO as compared to CTR, arbitrarily normalized to one. Data are
represented as the median values with interquartile range obtained by ten independent experiments and comparison with CTR was analyzed by Wilcoxon signed-rank
test (*p < 0.05;**p < 0.005). Comparison between the different TKI culturing conditions and the different DMSO dilution culturing conditions was analyzed by
Kruskal–Wallis multiple comparison test (*p < 0.05).
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FIGURE 2 | Dasatinib inhibits NK cell generation from CD34+ precursors. CD161+CD56+ cells developed in the absence (CTR) or in the presence of Imatinib 5µM
(IM), Nilotinib 3.6µM (NIL), Dasatinib 0.2µM (DAS) and DMSO 1:1000 (D 1:1000) were analyzed after 25 days of culture for the expression of the indicated surface
markers. (A) The histogram represents the fold change of CD161+CD56+CD117+, CD161+CD56+CD94/NKG2A+, and CD161+CD56+LFA-1+ cell percentages,
detected in the presence of the indicated TKI or DMSO, as compared to CTR cultures, arbitrarily normalized to one. Data are expressed as mean values ± SEM
obtained by ten independent experiments and analyzed by Wilcoxon signed-rank test (*p < 0.05;**p < 0.005). (B) The histogram represents the fold change of
CD161+CD56+ cell percentages expressing NKp46, NKp30, NKp44, NKG2D, DNAM-1, KIR, and CD16 receptors, developed in the presence of the indicated TKI or
DMSO as compared to CTR cultures, arbitrarily normalized to one. Data are expressed as mean values ± SEM of ten independent experiments and analyzed by
Wilcoxon signed-rank test (*p < 0.05). (C) Flow cytometric analyses show surface staining for the indicated surface markers expressed by CD161+CD56+ cells
obtained after 25 days of culture in the absence (CTR) or Dasatinib 0.2µM (DAS). Representative experiment out of ten.
the subset composition within the CD56+ cell population, similar
to those detected in the presence of Dasatinib. Thus, as shown in
Figures 5D,E, even in the presence of the lowest concentration of
KX2-391 (i.e., 5 nM), there was an increased expression of RORγt
TF and of CD117, paralleled by the reduced expression of Eomes
TF and of CD94/NKG2A. Accordingly, CD56+ cells undergoing
differentiation in the presence of Dasatinib 200 nM or KX2-391
5 nM, displayed a lower cytolytic activity against K562 target cells
as compared to control (Figure 5F).
It has been shown that Dasatinib can inhibit the Signal
Transducer and Activator of Transcription (STAT) 3 and STAT
5 protein phosphorylation through the inhibition of Src kinases.
Thus, the Dasatinib–mediated effects could also be due to
the inhibition of STAT3/STAT5 signaling pathways. To address
this issue we investigated whether Dasatinib could inhibit
STAT3/STAT5 phosphorylation in CD34+ cell precursors since
early days of in vitro culture. Thus, CD34+ cells were cultured
with cytokine mix medium in the absence or in the presence of
Dasatinib, and STATs protein phosphorylation was analyzed at
different time intervals, i.e., 18/24/48 h of culture. A reduction
of pSTAT5+ cell percentages was detected while the percentages
of pSTAT3+ cells were similar or higher than those detected in
control cultures at all the time intervals analyzed (Figure 6A).
Of note, after 72 h of culture in the presence of Dasatinib, we
could still observe lower pSTAT5+ cell percentages as compared
to control, and increase of CD117+ cell percentages (Figure 6B).
On the other hand, analysis performed at 20 days of culture,
showed that CD56+ cell subsets developed in the presence of
Dasatinib, contained higher percentages of pSTAT5+ cells as
compared to controls, while myeloid cells displayed a marked
reduction of both pSTAT3+ and pSTAT5+ cells (Figure 6C).
DISCUSSION
In this study we analyzed the effect of the TKI inhibitors
Imatinib, Nilotinib, and Dasatinib on NK cell differentiation
from UCB-derived CD34+ cell precursors. We show a sharp
inhibition of cell proliferation and a reduced recovery of both
myeloid and CD161+CD56+ lymphoid cells. More importantly,
Dasatinib skewed the subset composition of CD161+CD56+
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FIGURE 3 | Dasatinib affects the CD56+ cell repertoire, favoring the enrichment of CD56+CD117+CD94/NKG2A−RORγt+ ILC3. CD161+CD56+ cells developed in
the absence (CTR) or in the presence of Imatinib 5µM (IM), Nilotinib 3.6µM (NIL), Dasatinib 0.2µM (DAS) and DMSO 1:1000 (D 1:1000) were analyzed by
flow-cytometry after 25 days of culture for the expression of transcription factors (TF). (A) The histogram represents the fold change of CD56+RORγt+ and
CD56+EOMES+ cell percentages, obtained in the presence of the indicated TKI or DMSO, as compared to CTR, arbitrarily normalized to one. Data are expressed as
median values with interquartile range obtained by ten independent experiments and analyzed by Wilcoxon signed-rank test (**p < 0.005). (B) Dot plots show
intra-nuclear staining of RORγt and EOMES after gating on CD33−CD161+CD56+ cells, developed in the absence (CTR) or in the presence of the indicated TKI or
DMSO. Representative experiment out of ten performed. (C) UCB-CD34+ cells were purified and cultured with cytokine-mix medium in the absence (control=CTR) or
in the presence of Dasatinib 200 nM. After 6 days of culture cells were analyzed by flow-cytometry for the indicated surface markers. Flow cytometric analysis show
representative experiment out of two.
cell population favoring the generation of RORγt+IL-22+ ILC3
and inhibiting both proliferation and function of cytotoxic NK
cells. Experiments using the KX2-391 Src-family kinase inhibitor
suggest that the impairment of NK cell generation and function
may be consequent to the inhibitory effect mediated by Dasatinib
on Src-family kinases and the early impairment of STAT5
signaling in CD34+ cell precursors.
The TKI therapy in CML or Ph+ALL patients has dramatically
improved the prognosis of these patients. However, the
development of resistance and leukemia relapse, in particular
upon therapy discontinuation, still represents a major problem.
Thus, in recent years, a major research focus has been to
improve both DMR and TFR (8). Notably, a positive clinical
outcome in these patients appears to correlate with an efficient
immune response allowing the control of the CML residual
disease (13). Since NK cells are thought to play a relevant role
in this process, it was important to clarify whether TKI could
influence not only the repertoire and function of circulating
mature NK cells, but also their development from CD34+
HSC. To this end, we took advantage of an in vitro model
of NK cell differentiation from CD34+ cell precursors that
allows the generation of different ILC subsets. In addition, it
provides a useful tool to analyze factors/drugs that may modify
such process (27, 40). In the present experiments, CD34+
cells were cultured in the presence of Imatinib, Nilotinib, and
Dasatinib at plasmatic peak concentrations, to reproduce drug
concentrations present in PB and BM of TKI-treated patients.
An inhibitory effect of TKI on precursor cell proliferation
could be expected, since these compounds are known to
interfere with the SCF/c-KIT (CD117) transduction pathway that
plays a key role in the early steps of CD34+ cell activation
and proliferation (37, 41). However, the impairment of cell
proliferation and recovery was associated with an increase of
programmed cell death only in Dasatinib culture condition, in
which apoptosis was clearly detectable during the first week
of culture. Although all TKI analyzed induced a decrease of
CD161+CD56+ cell recovery, Dasatinib exerted a more marked
inhibitory effect. Moreover, only Dasatinib significantly skewed
the CD161+CD56+ cell repertoire favoring CD117+CD94−LFA-
1−-RORγt+ ILC3, while CD117−CD94+LFA-1+Eomes+ NK
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FIGURE 4 | Dasatinib increases the percentages of IL-22-producing CD56+CD117+CD94− and of IFN-γ-producing CD56+CD117+/−CD94+ cells while inhibits
cytolytic activity of CD56+ cells. After 25 days CD56+cells developed in the presence of Imatinib 5µM (IM), Nilotinib 3.6µM (NIL), Dasatinib 0.2µM (DAS) and DMSO
1:1000 (D 1:1000) were analyzed for the intra-cytoplasmic cytokine expression and for cell cytotoxicity. (A,B) CD56+ cells, developed in the absence or in the
presence of different TKI or DMSO 1:1000 were o.n. stimulated with IL-1β+IL-7+IL-23, to induce the production of IL-22 and TNF-α and IL-8 or with
IL-12+IL-15+IL-18, to favor the production of IFN-γ. Cells were analyzed for intra-cytoplasmic cytokine expression of IL-22, IL-8, IFN-γ, and TNF-α cytokines by flow
cytometry. (A) Flow cytometry analysis show representative experiment out of seven: dot plots represent the intra-cytoplasmic cytokine staining in
CD56+CD117+CD94/NKG2A− and CD56+CD117−/+ CD94/NKG2A+ cell subsets. (B) The histograms represent the fold change of IL-22, IL-8, IFN-γ, and TNF-α
positive cell percentages detected in CD56+CD117+CD94/NKG2A− and CD56+CD117−/+CD94/NKG2A+ cell subsets upon appropriate cytokine stimulation, as
compared to CTR, arbitrarily normalized to one. Data are expressed as mean percentage ± SEM of ten independent experiments and analyzed by Wilcoxon
signed-rank test (*p < 0.05). (C) The histogram shows the percentage cell lysis of human leukemic line K562 by CD161+CD56+ cells. Effector/target (E/T) cell ratio
was 2/1. Data are expressed as mean percentage ± SEM of four independent experiments and analyzed by Kruskal–Wallis multiple comparison test (*p < 0.05; **p <
0.005). (D) CD56+ cells were analyzed for intra-cytoplasmic expression of Perforin. Dot plots display Perforin intra-cytoplasmic staining in total CD56+ gated cells
and in CD56+LFA-1+(CD94+) gated cells. Representative experiment out of four performed.
cells were sharply reduced. The effect of Dasatinib on ILC
commitment was detectable at early stages, since analysis
performed at day 6 of culture revealed an increase of
CD117+CD127+CD132+ cells, representing ILC precursors,
while CD122 expression was undetectable. Previous studies on
factors that may influence human ILC in vitro development,
have shown that the presence of SCF is required to favor the
in vitro differentiation of ILC3 in the presence of IL-7 or IL-
15, while IL-15 and IL-7, alone or in combination with other
pro-inflammatory cytokines, skew precursor cell differentiation
toward NK cells (40, 42).
The SCF/c-kit transduction pathway involves STAT3 protein
phosphorylation, IL-15 pathway preferentially uses STAT5
signaling protein, while IL-7 can exploit both (37, 43). It has
been shown that Dasatinib inhibits the STAT3 and STAT5
signaling pathways through the inhibition of Src kinases, leading
to a durable inhibition of STAT5 phosphorylation, but only a
transient inhibition of STAT3 phosphorylation in CD34+ cells
isolated from CML patients at diagnosis (39). Our analysis
of STAT3/STAT5 phosphorylation in CD34+HSC revealed a
higher and durable reduction of pSTAT5+ cells as compared
to pSTAT3+ cells upon cell culture with Dasatinib during first
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FIGURE 5 | KX2-391 Src kinases inhibitor favors the development of CD56+CD117+RORγt+ cells, while inhibits generation and cytotoxicity of
CD56+CD94/NKG2A+EOMES+ cells. UCB-CD34+ cells were purified and cultured with cytokine-mix medium in the absence (control=CTR) or in the presence of
KX2-391 src kinase-inhibitor at different concentrations (5, 50, 100 nM) or Dasatinib at the plasma peak concentration (200 nM). (A) The histogram represents the
absolute cell numbers obtained after 15 days of culture, in the presence of KX2-391 inhibitor at different concentrations and Dasatinib, as compared to control,
arbitrarily normalized to one. The data are represented as mean±SEM obtained by nine independent experiments and analyzed by Wilcoxon signed-rank test (*p <
0.05; **p < 0.005). (B) Dot plots show the morphological features and Annexin V/PI staining observed in the cell precursors undergoing in vitro NK cell differentiation
in the presence of different culturing conditions: control (CTR), KX2-391 at different concentrations and Dasatinib. The cells were undergone to immunofluorescence
tests after 8 days of culture. (C) The histogram shows the fold change of CD161+CD56+ absolute cell number recovered after 15 days of culture in the presence of
KX2-391 inhibitor at different concentrations and Dasatinib, as compared to control, arbitrarily normalized to one. The data are represented as mean ±SEM obtained
by nine independent experiments and analyzed by Wilcoxon signed-rank test (*p < 0.05). (D) Box and Whiskers plots represent the fold change of CD56+RORγt+,
CD56+CD117+, CD56+EOMES+ and CD56+CD94/NKG2A+ cells, obtained after 25 days of culture in presence of KX2-391 5nM, as compared to control. The
data are obtained by seven independent experiments and analyzed by Wilcoxon signed-rank test (*p < 0.05). (E) Dot plots show analysis of CD94/NKG2A, RORγt
and EOMES TF in CD56+ cells, in the absence (= CTR) or in the presence of KX2-391 5 nM or Dasatinib 200 nM. Representative experiment out of three. (F) The
histogram represents the percentage cell lysis of human leukemic line K562 by CD161+CD56+ cells, after 27 days of culture, in the presence of KX2-391 5 nM and
Dasatinib 200 nM, as compared to control. Representative experiment out of two performed.
days of culture. Thus, it is conceivable that the early expression
of CD117 and CD127 on Dasatinib-treated cells may favor
the SCF/CD117- and IL-7/CD127–mediated STAT3 transduction
triggering pathway, thus favoring ILC precursors proliferation
and survival.
Functional analyses indicate that Dasatinib does not affect
cytokine production by ILC3 but rather induces increases of the
percentages of CD56+ CD117+RORγt+IL-22 producing cells.
Interestingly, the few NK cells, undergoing differentiation in
the presence of Dasatinib, contained higher percentages of IFN-
γ+cells. We also detected a slight increase of IL-8+/IFN-γ+ILC3
undergoing differentiation in the presence of Dasatinib. It has
been reported that lymphocyte mobilization in Dasatinib-treated
patients is frequently associated with adverse effects such as
pleural effusion, autoimmune-like syndromes and colitis (29).
Of note, ILC3 are thought to play a relevant role in intestinal
inflammation (25). In addition, they may exacerbate intestinal
inflammation due to their ability to differentiate toward IFN-
γ-producing ILC1 cells upon IL-12 stimulation (44). Thus, the
inflammatory side effects induced byDasatinib inmucosal tissues
may reflect, at least in part, increases in the production of IL-22,
IL-8, and IFN-γ by ILC. Of note, the increase of IFN-γ-expressing
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FIGURE 6 | Analysis of the Dasatinib-mediated effect on STAT3 and STAT5 phosphorylation in CD34+ cells undergoing differentiation toward CD56+cells at different
culture time intervals. (A) UCB-CD34+ cells were isolated and cultured with cytokine-mix medium, in the absence or in the presence of Dasatinib 200 nM for 18, 24,
and 48 h. Cells were analyzed for the expression of pSTAT3 and pSTAT5 signaling proteins. The histograms show the fold changes of CD34+pSTAT3+ and
CD34+pSTAT5+ positive cell percentages detected in the presence of Dasatinib, as compared to control, arbitrarily normalized to one. Data are expressed as mean
values ± SEM obtained by four independent experiments. (B) UCB-CD34+ cells were isolated and cultured with cytokine-mix medium, in the absence or in the
presence of Dasatinib 200 nM for 72 h. Flow cytometry analyses show the intra-cytoplasmic expression of pSTAT3 and pSTAT5 on total cell population and on
CD14−CD117+ gated cells. (C) CD56+ cells obtained from UCB-CD34+ cells after 20 days of culture, in the absence (CTR) or in the presence of Dasatinib 200 nM
were analyzed for the expression of pSTAT3 and pSTAT5 signaling proteins. The histogram shows the fold change of CD56+pSTAT3+ and CD56+pSTAT5+ cell
percentages detected in the presence of Dasatinib, as compared to control, arbitrarily normalized to one. Data are expressed as mean values ± SEM obtained by four
independent experiments.
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FIGURE 7 | Schematic representation of potential effects of Dasatinib on IL-7/IL-15 transduction pathways. IL-7 and IL-15 cytokines can signal both through the
JAK-STAT and the Src pathways.After 20 days of culture, in the control condition, the cytokine receptors engagement by IL-7 and IL-15 leads both to JAK- and Src-
STAT-mediated recruitment and phosphorylation. In the presence of Dasatinib, Src-mediated STAT phosphorylation pathway is abrogated, while cytokine-driven
JAK-activation pathway would provide compensatory signals, allowing STAT5 phosphorylation.
CD56+ cells detectable after 25 days of culture in the presence
of Dasatinib, paralleled the increase of CD56+pSTAT5+cell
percentages. These data may suggest that a prolonged exposure
to IL-7 and IL-15 may provide compensatory signals, allowing
lymphoid cell cytokine production even in the presence of a
chronic exposure to Dasatinib (45) (Figure 7).
The cytolytic activity of CD56+ NK cells developed in the
presence of Dasatinib was impaired. It is conceivable that the
reduction of cytotoxicity may reflect the lower number of mature
NK cells however, we could also detect a decrease of Perforin
content in the few mature NK cells present in Dasatinib cultures.
In addition, it should be considered the inhibitory effect exerted
by Dasatinib on Src kinases and on ERK protein phosphorylation
(p-ERK), required for the cytolytic degranulation process (39,
46, 47). Indeed, our experiments using KX2-391 inhibitor would
confirm that the effect on the CD56+ cell repertoire induced
by Dasatinib, may be due to the impairment of Src kinase
pathway. Notably, KX2-391 induced massive cell apoptosis at
the concentration of 200 nM while at lower concentrations
the proportions of Annexin V+ cells were low. However, the
use of KX2-391 at lower concentrations skewed the CD56+
cell repertoire toward CD56+CD117+CD94/NKG2A− RORγt+
ILC3, similar to what detected in cultures performed in the
presence of Dasatinib.
Studies in mice models have suggested that IL-15/STAT5
pathway may represent a central node in NK cell homeostasis
and in the TF network that instructs ILC development (48–
51). Our data indicate that exposure to Src kinase inhibitors
may play a relevant a role in the inhibition of human NK
cell development and in the acquisition of cytolytic activity,
while the cytokine-driven STAT3 and STAT5 activation pathway
may overcome Dasatinib-mediated inhibition and favor the
preferential survival of CD117+ CD127+ ILC3 precursors and
the subsequent cytokine production by both mature ILC3 and
NK cells detectable at later time culture intervals.
It has been reported that Dasatinib, may induce cytotoxic
CD56+CD57+ NK cell mobilization in the PB and BM of TKI-
treated patients (29–31, 52). It is conceivable that different
effects detectable in vitro vs. in vivo of Dasatinib-treatment
may be consequent to the short half-life of the drug in plasma
vs. its stable levels in cell cultures (53). Notably, it has been
suggested that the incidence of lymphocytosis does not correlate
with DMR, while the numbers and percentages of circulating
cytotoxic NK cells and CTL were significantly higher in patients
with DMR as compared to those with no DMR (30). The
high degree of heterogeneity of cases analyzed may contribute
to the variability of responses: patients may undergo different
TKI administration protocols, and the immune system status
(immunosuppression, viral reactivation, therapy-related BM/
lymphoid organs exhaustion) may greatly influence immune cell
repertoire and function, having an impact on the clinical outcome
of CML-treated patients (13).
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In conclusion, our results suggest that Dasatinib may
affect NK cell development, and offer new clues to better
understand the signaling pathways that regulate development
and proliferation of precursors toward NK cells and other
ILC. The Dasatinib-induced skewing of ILC differentiation
toward ILC3 and increasing of IFN-γ producing cells should be
considered in patients with severe therapy-induced side effects
or with limited responses to therapy. Moreover, in Dasatinib-
treated patients, it will be important to better characterize both
the lymphoid cell precursors and the mature cytolytic effector
cells present in patients BM, i.e., the site where drug-resistant
leukemic clones primarily reside (54). Finally, our study, could
offer a clue for identifying new tools to design individualized
timing and dosing of Dasatinib administration in order to obtain
optimal responses without compromising the NK cell-based
immunotherapeutic intervention.
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